Inhibition of the ubiquitin-proteasome pathway has been validated as a cornerstone of therapy for multiple myeloma by pre-clinical and clinical studies from our group and others. However, response rates among patients in the relapsed and refractory setting for bortezomib and carfilzomib, the two proteasome inhibitors that have garnered regulatory approvals, are less than 50% and 25%, respectively, and both are associated with significant toxicities. Moreover, patients are currently treated empirically, since no markers of proteasome inhibitor sensitivity have been identified, and even patients who initially respond eventually develop resistant disease through poorly understood mechanisms. Our preliminary studies have identified tight junction protein (TJP) 1 as a key modulator of proteasome inhibitor sensitivity through its ability to influence the balance in plasma cells between the proteasome load and capacity, a key determinant of myeloma responsiveness to proteasome inhibition. Furthermore, manipulation of TJP1 activity and expression is able to achieve chemosensitization and overcome chemoresistance to proteasome inhibitors. Together, these findings support our central hypothesis, which proposes that TJP1 is both a candidate biomarker of proteasome capacity and proteasome inhibitor sensitivity in myeloma, and a target for novel approaches to enhance the efficacy of this class of agents. To evaluate these possibilities, additional studies are proposed to further delineate the mechanisms by which TJP1 exerts its effects on proteasome subunit synthesis, and therefore capacity. In addition, genomic studies will be performed in association with prospective cooperative group trials of bortezomib and carfilzomib to validate the possibility that TJP1 expression may help to identify patients who are most and least likely to benefit from proteasome inhibitor-based therapy. Finally, approaches to enhance the activity of TJP1, including inhibitors of the epidermal growth factor receptor and Janus kinases/signal transducer and activator of transcription 3, and also approaches to enhance TJP1 expression, such as with hypomethylating agents, will be evaluated for their ability to induce chemosensitization, and overcome chemoresistance in cell lines, primary samples, and physiologically relevant in vivo murine models.

Public Health Relevance

Successful completion of this research effort will expand basic knowledge about the pathways involved in modulating the protein turnover capacity of the ubiquitin-proteasome pathway, identify promising translational approaches to enhance the activity of proteasome inhibitors and overcome resistance to these agents, and validate the first biomarker of proteasome capacity and clinical sensitivity to proteasome inhibition.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Developmental Therapeutics Study Section (DT)
Program Officer
Kondapaka, Sudhir B
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
Internal Medicine/Medicine
Other Domestic Higher Education
United States
Zip Code
Ni, Haiwen; Shirazi, Fazal; Baladandayuthapani, Veerabhadran et al. (2018) Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. Clin Cancer Res 24:6408-6420
Zhang, Xiaohui; Lee, Hans C; Shirazi, Fazal et al. (2018) Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma. Leukemia 32:2224-2239
Hao, Suyang; Lin, Pei; Medeiros, L Jeffrey et al. (2017) Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion. Mod Pathol 30:1378-1386
Purushothaman, Anurag; Bandari, Shyam K; Chandrashekar, Darshan S et al. (2017) Chondroitin sulfate proteoglycan serglycin influences protein cargo loading and functions of tumor-derived exosomes. Oncotarget 8:73723-73732
Baljevic, Muhamed; Zaman, Shadia; Baladandayuthapani, Veerabhadran et al. (2017) Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma. Ann Hematol 96:977-985
Wang, Hua; Baladandayuthapani, Veerabhadran; Wang, Zhiqiang et al. (2017) Truncated protein tyrosine phosphatase receptor type O suppresses AKT signaling through IQ motif containing GTPase activating protein 1 and confers sensitivity to bortezomib in multiple myeloma. Oncotarget 8:113858-113873
Manasanch, Elisabet E; Orlowski, Robert Z (2017) Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol 14:417-433
Lee, Hans C; Wang, Hua; Baladandayuthapani, Veerabhadran et al. (2017) RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma. Br J Haematol 177:80-94
Carballo-Zarate, Adrian A; Medeiros, L Jeffrey; Fang, Lianghua et al. (2017) Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience. Mod Pathol 30:843-853
Zhang, Yu; Zhou, Liang; Leng, Yun et al. (2017) Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma. Oncotarget 8:59476-59491

Showing the most recent 10 out of 20 publications